Facility
Catalent (Novo Nordisk) - Bloomington, Indiana
Operated by Catalent (acquired by Novo Nordisk) →US
Converted to dedicated Novo Nordisk GLP-1 drug product manufacturing after $16.5B acquisition 2024; fill-finish for Ozempic/Wegovy autoinjector pens
0
Inputs produced
0
Goods downstream
0
Incidents on record
0
Stories